MMRGlobal Announces International Music Star Guy Sebastian as Spokesperson and Personal Health Records Ambassador

LOS ANGELES, CA--(Marketwired - Jul 29, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") welcomes International Music Star Guy Sebastian as MyMedicalRecords' Australian Spokesperson to Los Angeles. MMRGlobal CEO Robert H. Lorsch met with Sebastian to discuss plans to launch a "Don't Worry Be Happy" campaign (www.guysebastian.com.au) to call attention to how the safety and security from having a Personal Health Record (PHR) can prevent worry and help promote a happier healthier lifestyle. The MMR products and services that are the focus of the campaign will include the Company's MyMedicalRecords PHR as well as a version of its MyEsafeDepositBox. All monies payable to Sebastian under the terms of his agreement with MMR will be contributed to the Sebastian Foundation or other charity specified by Sebastian. Designated charities also would include The Children's Hospital at Westmead in Sydney, the International Red Cross, and World Vision Australia.

According to Guy Sebastian, "I love the idea of using the title of my song "Don't Worry Be Happy" from my new album Armageddon to urge people to open a MyMedicalRecords account (https://itunes.apple.com/au/album/armageddon/id566246842). The whole idea of having a Personal Health Record is so you don't have to worry in case of a disaster, emergency or illness because you are prepared for anything. Having an MMR account helps people live happier, healthier lives."

Guy Sebastian is an Australian pop, R&B, and soul singer-songwriter who is touring with Taylor Swift beginning December 2013. Sebastian was the first winner of Australian Idol in 2003 and went on to be a judge on Australia's The X Factor. His latest album Armageddon is available everywhere. Sebastian has released seven top ten albums, with six reaching the top five, including two which peaked at number one. They have all achieved either platinum or multi-platinum certification. He has also released 11 top ten singles, including six number ones, and three other top 15 singles. Sebastian is the only Australian male artist in Australian chart history to achieve six number one singles, and he is third overall for all Australian acts. Guy Sebastian is managed by 6 Degrees Management (http://www.6degreesmanagement.com.au/home/).

According to Lorsch, "Guy Sebastian is a great star with a huge worldwide following which makes him the perfect person to bring awareness to the importance of having a Personal Health Record. His music is dedicated to bringing the world together. Our products and services are all about bringing families' important personal health information together wherever they are in the world. MMR's plan is to leverage its MyMedicalRecords brand by taking advantage of global healthcare reform to offer our patented products and services and other intellectual property already issued, pending or applied for in 13 countries, including Australia."

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.

Forward-Looking Statements
All statements in this press release that are not strictly historical in nature, whether or not such statement relates to the Company's investigations surrounding its patents in Australia, and including, without limitation, future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties, including those surrounding the Company's having not yet completed its investigation and determination of whether or not infringement exists in Australia, and other factors that may cause the Company's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "appear," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors, charitable organizations, and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property investigation and enforcement actions, claims of intellectual property infringement and general intellectual property litigation in the U.S. and internationally; our ability to maintain, develop, monetize and protect our patent portfolio for both the Company's health IT and biotechnology intellectual property assets; the timing of milestone payments in connection with licensing our intellectual property; the risk the Company's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in the Company's filings with the SEC. The Company is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.